SCHEMBL295744

SCHEMBL295744

COC(=O)C(F)(CCBr)c1ccc(Cl)c(Cl)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.43
MCHR1 Q99705 1/20 0.43
TSHR P16473 1/20 0.39
MAPT P10636 5/20 0.39
NPSR1 Q6W5P4 3/20 0.39
MAPK1 P28482 1/20 0.39
NR1H2 P55055 1/20 0.38
NR1H3 Q13133 1/20 0.38
TRPV1 Q8NER1 1/20 0.38
KDM4E B2RXH2 1/20 0.38
SSTR4 P31391 1/20 0.37
HPGD P15428 1/20 0.37
LMNA P02545 2/20 0.36
MEN1 O00255 4/20 0.36
KMT2A Q03164 4/20 0.36
NPC1 O15118 2/20 0.36
CYP1A2 P05177 2/20 0.36
CYP3A4 P08684 2/20 0.36
CYP2C19 P33261 2/20 0.36
CYP2D6 P10635 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL371221 0.86 SMN1; SMN2 (0.43) SMN1; SMN2MCHR1TSHRMAPTNPSR1
SCHEMBL296610 0.82 SSTR4 (0.40) SMN1; SMN2MCHR1TSHRMAPTNPSR1
SCHEMBL3170901 0.72 SMN1; SMN2 (0.47) SMN1; SMN2MCHR1TSHRMAPTNPSR1
SCHEMBL1627157 0.72 CNR1 (0.51) SMN1; SMN2MCHR1TSHRMAPTSSTR4
SCHEMBL10789216 0.72 SMN1; SMN2 (0.47) SMN1; SMN2MCHR1TSHRMAPTNPSR1
SCHEMBL295868 0.72 KCNH2 (0.41) SMN1; SMN2MCHR1NPSR1MEN1KMT2A
SCHEMBL27932320 0.71 SMN1; SMN2 (0.46) SMN1; SMN2MCHR1TSHRMAPTNPSR1
SCHEMBL30730313 0.68 MAPT (0.53) SMN1; SMN2TSHRMAPTNPSR1MAPK1
SCHEMBL11001322 0.68 SMN1; SMN2 (0.43) SMN1; SMN2MCHR1TSHRMAPTNPSR1
SCHEMBL7408847 0.68 SMN1; SMN2 (0.41) SMN1; SMN2MCHR1TSHRMAPTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2200982-B1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS HOFFMANN LA ROCHE (CH) 2012-03-14 EP disclosed
US-20110021565-A1 PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS KNUST HENNER 2011-01-27 US disclosed
US-20110021565-A1 PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS KNUST HENNER 2011-01-27 US disclosed
US-20110021565-A1 PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS KNUST HENNER 2011-01-27 US disclosed
EP-2200982-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS F. Hoffmann-Roche AG (CH) 2010-06-30 EP disclosed
WO-2009033995-A1 PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2009-03-19 WO disclosed
US-20090076081-A1 PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2009-03-19 US disclosed
US-20090076081-A1 PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2009-03-19 US disclosed
US-20090076081-A1 PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2009-03-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090076081-A1 PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS DRD2, DRD3, OPRL1 SMN1; SMN2 1251/4885MCHR1 403/4885TSHR 822/4885
US-20110021565-A1 PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS DRD2, DRD3, OPRL1 SMN1; SMN2 1251/4885MCHR1 403/4885TSHR 822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.